| Triumph or tragedy: progress in cancer | Ayşe Şebnem ERENLER,Hikmet GEÇKİL | 701–707 |
| Aging and cancer: molecular facts and awareness for Turkey | Gülgün GÜNDÜZ,Kayahan FIŞKIN | 708–719 |
| Autophagy and cancer | Hacer Ezgi KARAKAŞ,Devrim GÖZÜAÇIK | 720–739 |
| Invadopodia: proteolytic feet of cancer cells | Gizem BATI,Devrim Pesen OKVUR | 740–747 |
| It takes 2 antioxidants to tango: the interaction between manganese superoxide dismutase and glutathione peroxidase-1 | Dede N. EKOUE,Alan M. DIAMOND | 748–753 |
| Glycosylation changes leading to the increase in size on the common core of N-glycans, required enzymes, and related cancer-associated proteins | Sabire KARAÇALI,Savaş İZZETOĞLU,Remziye DEVECİ | 754–771 |
| Progesterone receptor modulators in breast cancer | Ronald D. WIEHLE | 772–785 |
| Failure of immunological cells to eradicate tumor and cancer cells: an overview | Rohit SHARMA,Daizee TALUKDAR,Parth MALIK,Tapan Kumar MUKHERJEE | 786–799 |
| The role of ABC transporters in anticancer drug transport | Serhan KARVAR | 800–805 |
| Multidrug resistance in chronic myeloid leukemia | Miray ÜNLÜ,Yağmur KİRAZ,Fatma Necmiye KACI,Mehmet Ali ÖZCAN,Yusuf BARAN | 806–816 |
| Noncoding RNAs and cancer | Hesna Begüm AKMAN,Ayşe Elif Erson BENSAN | 817–828 |
| Cancer stem cells: emerging actors in both basic and clinical cancer research | Didem KARAKAŞ,Buse CEVATEMRE,Engin ULUKAYA | 829–838 |
| Current paradigms of cancer chemoprevention | Rajendra G. MEHTA | 839–847 |
| Evaluation of MUC1, CK20, and hTERT expression in peripheral blood of gastrointestinal cancer patients in search of diagnostic criteria | Sibel KÜÇÜKYILDIRIM,Beril ERDEM,Emel SAĞLAR,Zülfikar POLAT,Hatice MERGEN | 848–857 |